DOCSLIB.ORG

Adrenergic Receptor Beta Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adrenergic Receptor Beta Receptor Adrenergic Receptor Beta Receptor Adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially norepinephrine and epinephrine. Many cells possess these receptors, and the binding of a catecholamine to the receptor will generally stimulate the sympathetic nervous system. The sympathetic nervous system is responsible for the fight-or-flight response, which includes widening the pupils of the eye, mobilizing energy, and diverting blood flow from non-essential organs to skeletal muscle. There are two main groups of adrenergic receptors, α and β, with several subtypes. α receptors have the subtypes α1 and α2. β receptors have the subtypes β1, β2 and β3. All three are linked to Gs proteins, which in turn are linked to adenylate cyclase. Agonist binding thus causes a rise in the intracellular concentration of the second messenger cAMP. Downstream effectors of cAMP include cAMP-dependent protein kinase (PKA), which mediates some of the intracellular events following hormone binding. www.MedChemExpress.com 1 Adrenergic Receptor Agonists, Antagonists, Inhibitors, Activators & Modulators (+)-Penbutolol (4E)-SUN9221 ((R)-Penbutolol; (+)-Isopenbutolol) Cat. No.: HY-116790A Cat. No.: HY-U00367 (+)-Penbutolol is a β-adrenoceptor antagonist, (4E)-SUN9221 is a potent antagonist of with an IC50 of 0.74 μM. (+)-Penbutolol is an α1-adrenergic receptor and 5-HT2 receptor, with optical isomer of l-penbutolol with Na+ antihypertensive and anti-platelet aggregation channel-blocking action. activities. Purity: >95.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg (R)-(+)-Atenolol (R)-Carvedilol Cat. No.: HY-B2111 ((R)-BM 14190) Cat. No.: HY-B0006C (R)-(+)-Atenolol is the less active enantiomer of (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of the (R,S)-atenolol. (R,S)-atenolol is a Carvedilol, is a non-selective β/α-1 blocker. β-adrenergic receptor antagonist. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX). Purity: >99.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 1 mg, 5 mg (R)-Terazosin (Rac)-Rotigotine hydrochloride Cat. No.: HY-B0371B Cat. No.: HY-15394 (R)-Terazosin is an active R-enantiomer of (Rac)-Rotigotine hydrochloride is a racemate of Terazosin. (R)-Terazosin is a potent Rotigotine. α1-adrenoceptor antagonist with Ki values of 6.51 nM, 1.01 nM and 1.97 nM for α1a, α1b and α1d-adrenoceptor, respectively. Purity: 99.77% Purity: 97.76% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg (RS)-Butyryltimolol (S)-Carvedilol Cat. No.: HY-102032A ((S)-BM 14190) Cat. No.: HY-B0006B (RS)-Butyryltimolol is the racemate of (S)-Carvedilol, the S-enantiomer of Carvedilol, is Butyryltimolol. Butyryltimolol, an effective a non-selective β/α-1 blocker. (S)-Carvedilol prodrug of Timolol, improves the corneal exerts protection against the vascular or cardiac penetration of Timolol. Butyryltimolol is a toxicity of Doxorubicin (DOX). β-adrenergic blocker. Purity: >98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg (S)-Terazosin (S)-Timolol Maleate Cat. No.: HY-B0371D (L-714,465 Maleate; MK 950) Cat. No.: HY-17380 (S)-Terazosin is an active S-enantiomer of (S)-Timolol Maleate (L-714,465 Maleate) is a Terazosin. (S)-Terazosin is a potent and non-cardioselective hydrophilic β-adrenoceptor high-affinity α-adrenoceptor antagonist with Ki blocker. (S)-Timolol Maleate is widely used as values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, standard medication for intraocular pressure α1b and α1d-adrenoceptor, respectively. (glaucoma) by preventing the production of aqueous humor. Purity: 99.77% Purity: 99.85% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 100 mg, 200 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] (±)-Befunolol (±)-Bisoprolol hemifumarate Cat. No.: HY-101752 (Bisoprolol hemifumarate salt) Cat. No.: HY-B0076 (±)-Befunolol is a β-adrenoceptor blocking agent. (±)-Bisoprolol (hemifumarate) is a selective type β1 adrenergic receptor blocker. Target: Adrenergic Receptor Approved: July 31, 1992 Bisoprolol, on beta 1-adrenoceptor peptide induced autoimmune myocardial damage. Purity: >98% Purity: 99.65% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg 2',5'-Dideoxyadenosine 4-Hydroxypropranolol D7 hydrochloride Cat. No.: HY-135878 ((±)-4-hydroxy Propranolol D7 hydrochloride) Cat. No.: HY-100634S 2',5'-Dideoxyadenosine is a potent and 4-Hydroxypropranolol D7 hydrochloride non-competitive adenylyl cyclase inhibitor via ((±)-4-hydroxy Propranolol D7 hydrochloride) is a binding the P-site with an IC50 of 3 µM . deuterium labeled 4-Hydroxypropranolol 2',5'-Dideoxyadenosine is a nucleoside analog and hydrochloride. exerts a potent antiadrenergic action in heart. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg, 250 mg Size: 1 mg, 5 mg 4-Hydroxypropranolol hydrochloride 5-HT2 antagonist 1 ((±)-4-hydroxy Propranolol hydrochloride) Cat. No.: HY-100634 Cat. No.: HY-U00365 4-Hydroxypropranolol hydrochlorid is an active 5-HT2 antagonist 1 is a potent antagonist of metabolite of Propranolol. 4-Hydroxypropranolol 5-HT2 receptor, with weak α1 adrenoceptor hydrochlorid is of comparable potency to blocking activity. Propranolol. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg Aaptamine Acebutolol D7 Cat. No.: HY-N4225 Cat. No.: HY-17497S Aaptamine, a spongean alkaloid isolated from a sea Acebutolol D7 is a deuterium labeled Acebutolol. sponge Aaptos aaptos, is a competitive antagonist Acebutolol is a selective β1 adrenergic receptor of α-adrenoceptor and activates the p21 promoter antagonist used in the treatment of hypertension, in a p53-independent manner. angina pectoris and cardiac arrhythmias. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg Acebutolol hydrochloride ACTH (1-14) Cat. No.: HY-17497A (Adrenocorticotropic Hormone Fragment 1-14) Cat. No.: HY-P1582 Acebutolol hydrochloride is a β1 adrenergic ACTH (1-14) is a fragment of adrenocorticotrophin, receptor (β1AR) antagonist. Acebutolol which regulates cortisol and androgen production. hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias. Purity: 99.95% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 5 g, 10 g Size: 1 mg, 5 mg www.MedChemExpress.com 3 ACTH (1-14) (TFA) ADRA1D receptor agonist 1 (Adrenocorticotropic Hormone Fragment 1-14 TFA) Cat. No.: HY-P1582A Cat. No.: HY-135270 ACTH (1-14) (TFA) is a fragment of ADRA1D receptor agonist 1 (compound (R)-9S) is a adrenocorticotrophin, which regulates cortisol and potent, selective and orally active α1D androgen production. adrenoceptor antagonist, with a Ki of 1.6 nM. Purity: 98.55% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg AGN 192836 Ajmalicine Cat. No.: HY-100300 (Raubasine) Cat. No.: HY-N1919 AGN 192836 is a potent and selective α2 adrenergic Ajmalicine (Raubasine) is found in herbs of agonist with EC50s of 8.7, 41 and 6.6 nM for Catharanthus roseus, is an antihypertensive drug α2A, α2B and α2C receptor, respectively. used in the treatment of high blood pressure, decreases peripheral resistance and blood pressure. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg Alfuzosin Alfuzosin hydrochloride (SL 77499) Cat. No.: HY-B0192 (SL 77499-10) Cat. No.: HY-B0192A Alfuzosin is an α1 adrenergic receptor antagonist Alfuzosin hydrochloride is an α1 adrenergic used to treat benign prostatic hyperplasia (BPH). receptor antagonist used to treat benign prostatic hyperplasia (BPH). Purity: 99.81% Purity: 98.73% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 10 mM × 1 mL, 10 mg, 50 mg Amezinium methylsulfate Amibegron hydrochloride (Amezinium metilsulfate; Lu-1631) Cat. No.: HY-A0275 (SR 58611A) Cat. No.: HY-103207 Amezinium metilsulfate has multiple mechanisms, Amibegron hydrochloride is a selective including stimulation of alpha and beta-1 β3-adrenoceptor agonist, with an EC50 of 3.5 nM receptors and inhibition ofnoradrenaline and for β-adrenoceptor in rat colon; Amibegron tyramine uptake. hydrochloride has anxiolytic and antidepressant activity. Purity: 99.51% Purity: >99.0% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g Size: 5 mg Amitraz Ancarolol (BTS-27419) Cat. No.: HY-B1111 Cat. No.: HY-100141 Amitraz is a non-systemic acaricide and Ancarolol is a beta-adrenergic blocking agent. insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis. Purity: >98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 1 mg, 5 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] AR-08 Arbutamine Cat. No.: HY-U00371 Cat. No.: HY-16056 AR-​08 is an agonist of α2-adrenergic receptor, Arbutamine is a short-acting synthetic potent used for the treatment of attention deficit nonselective β-adrenoceptor agonist that hyperactivety disorder (ADHD).
Load more

Recommended publications
  • UC San Francisco Electronic Theses and Dissertations
    UCSF UC San Francisco Electronic Theses and Dissertations Title Machine Learning for Medical Image Analysis and Compound-Target Interactions Permalink https://escholarship.org/uc/item/8c54b5m7 Author Gaskins, Garrett Publication Date 2020 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Machine Learning for Medical Image Analysis and Compound-Target Interactions by Garrett Gaskins DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biological and Medical Informatics in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Michael J Keiser Chair ______________________________________________________________________________Jason Gestwicki ______________________________________________________________________________Sourav Bandyopadhyay ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2020 by Garrett Gaskins ii ACKNOWLEDGEMENTS The graduate process is quite an experience. There is a subtle difficulty in describing it, as a peculiar quality of its existence is defined by the uniqueness of it all. Everyone I’ve known to be a part of or to have gone through graduate school has described a truly different journey. Perhaps this is integral to what makes the whole thing work. At the least,
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi
    Original article • Articolo originale Beyond monoamines towards the development of novel antidepressants Oltre le monoamine al fine di sviluppare nuovi farmaci antidepressivi M. Fornaro1,2 1 Department of “Scienze della Formazione”, University of Catania, Italy; 2 Department of Psychiatry, Veteran Affairs (VA) Hospital, University of California (UCSD), La Hoya, San Diego, CA, USA Summary ated giving priority to RCTs and meta-analyses. At present, the pharmacological management of depression appears is Objective characterized by a wide variety of different augmentation or Herein, a concise review is presented on the current and most switching approaches (Fig. 1). Nonetheless, response rates promising antidepressant pharmacological agents for manage- remain substantially unsatisfactory, thus prompting for the ment of depression. development of novel agents with different mechanisms of action. Materials and methods A PubMed search (1966 - February 2012) was performed using Conclusions the following keywords or their combination: “depression”; Shifting the interest for novel antidepressant drugs beyond the “major depressive disorder”: “antidepressants”; “novel antide- monoaminergic modulation represents (Tables I-III) an intriguing pressant targets”; “monoamine”; “novel antidepressants”. Ad- opportunity to enhance response rates of depression, although ditional literature sources, including most authoritative and up- other issues, including revision of current nosological bounda- dated edited books or pamphlets were examined accordingly.
    [Show full text]
  • Pharmacology in MS Advanced Practice Management
    Pharmacology in MS Advanced Practice Management Heidi Maloni APRN, BC [email protected] Objectives • Discuss basic principles of pharmacology, pharmacokinetics and pharmacodynamics. • Describe the pharmacotherapeutics of drugs used in MS • Identify the role of advanced practice nurse in MS pharmacological management. Advanced Practice Pharmacology Background • Pharmacology: study of a drug’s effects within a living system • Each drug is identified by 3 names: chemical, generic, trade or marketing name N-4-(hydroxyphenyl) acetamide; acetaminophen; Tylenol sodium hypochlorite; bleach; Clorox 4-(diethylamino)-2-butynl ester hydrochloride; oxybutynin chloride; Ditropan • Drugs are derived from: plants, humans, animals, minerals, and chemical substances • Drugs are classified by clinical indication or body system APN Role Safe drug administration Nurses are professionally, legally, morally, and personally responsible for every dose of medication they prescribe or administer Know the usual dose Know usual route of administration Know significant side effects Know major drug interactions Know major contraindication Use the nursing process Pregnancy Safety • Teratogenicity: ability to produce an abnormality in the fetus (thalidomide) • Mutogenicity: ability to produce a genetic mutation (diethylstilbestrol, methotrexate) Pregnancy Safety Categories • A: studies indicate no risk to the fetus (levothyroxan; low dose vitamins, insulin) • B: studies indicate no risk to animal fetus; information in humans is not available (naproxen;acetaminophen; glatiramer
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • List of Substances Under PSUR WS Scheme and Other Substances
    ABCDEFGHIJKL List of substances under PSUR Work Sharing scheme and other substances contained in Nationally Authorised Products with DLP synchronised Status July 2013 In brown font: changes made since last publication on 30th June 2013 1 Are PSURs required for Substances under PSUR Submission of Innovator brand products referred Work Sharing scheme PSURs by name (for fixed DLP (year Allocated PRMS / Note on PSUR to in Articles or Others (contained in Active substance name (INN) EU HBD Firm's Name Comments Next DLP (DLP + 90 combination and month) Procedure number cycle 10(1), 10a, 14 and Nationally Authorised days by products only) 16a of Directive Products including default) 2001/83/EC as MRP/DCP) 2 amended? sulbactam No, except if required nationally 19871116 201311 Pfizer AT/H/PSUR/0004/003 201402 Work Sharing by a competent 3 authority idarubicin No, except if required nationally 19891129 201311 Pfizer AT/H/PSUR/0005/003 201402 Work Sharing by a competent 4 authority dexibuprofen No, except if required nationally 20000725 31/08/2014 Gebro Pharma AT/H/PSUR/0009/003 29/11/2014 Work Sharing by a competent 5 authority nicorandil No, except if required nationally 19900209 201302 Merck AT/H/PSUR/0023/002 201305 Work Sharing by a competent 6 authority azelastine Request from MEDA Pharma GmbH & Co.KG to amend the DLP to 31/12/2014. Request agreed by the P- No, except if RMS AT. The substance has required nationally 20/11/1990 201309 Meda been moved to the EURD AT/H/PSUR/0038/001 201312 Work Sharing by a competent list as detailed in the
    [Show full text]
  • National Horizon Scanning Centre Amibegron
    National Horizon Scanning Centre Amibegron (SR–58611) for depression April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The National Horizon Scanning Centre Research Programme is part of the National Institute for Health Research April 2008 National Horizon Scanning Centre News on emerging technologies in healthcare Amibegron (SR–58611) for depression Target group • Major depressive disorder (MDD). Technology description Amibegron is a selective beta 3-adrenoceptor, which stimulates neuronal activity in a specific area of the prefrontal cortex. Amibegron is an oral formulation administered at 175mg or 350mg twice daily. Innovation and/or advantages Amibegron is the first in a new class of antidepressant agents. It is anticipated that it will have less toxicity than current treatments. Developer Sanofi-Aventis. Availability, launch or marketing dates, and licensing plans: In phase III clinical trials. NHS or Government priority area: This topics relates to the National service framework for mental health: modern standards and service models. 19991. Relevant guidance • NICE technology appraisal. Depression and anxiety - Computerised cognitive behaviour therapy for depression and anxiety. 20062. • NICE clinical guideline in development. Depression - primary and secondary care: The treatment and management of depression in primary and secondary care. Expected June 20093. • NICE clinical guideline in development. Depression - chronic health problems: The treatment of depression in people with chronic physical health problems. Expected June 20094. • NICE clinical guideline.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]